241 related articles for article (PubMed ID: 30884329)
1. Achieving cross-reactivity with pan-ebolavirus antibodies.
King LB; Milligan JC; West BR; Schendel SL; Ollmann Saphire E
Curr Opin Virol; 2019 Feb; 34():140-148. PubMed ID: 30884329
[TBL] [Abstract][Full Text] [Related]
2. Macaque Monoclonal Antibodies Targeting Novel Conserved Epitopes within Filovirus Glycoprotein.
Keck ZY; Enterlein SG; Howell KA; Vu H; Shulenin S; Warfield KL; Froude JW; Araghi N; Douglas R; Biggins J; Lear-Rooney CM; Wirchnianski AS; Lau P; Wang Y; Herbert AS; Dye JM; Glass PJ; Holtsberg FW; Foung SK; Aman MJ
J Virol; 2016 Jan; 90(1):279-91. PubMed ID: 26468532
[TBL] [Abstract][Full Text] [Related]
3. Pan-ebolavirus and Pan-filovirus Mouse Monoclonal Antibodies: Protection against Ebola and Sudan Viruses.
Holtsberg FW; Shulenin S; Vu H; Howell KA; Patel SJ; Gunn B; Karim M; Lai JR; Frei JC; Nyakatura EK; Zeitlin L; Douglas R; Fusco ML; Froude JW; Saphire EO; Herbert AS; Wirchnianski AS; Lear-Rooney CM; Alter G; Dye JM; Glass PJ; Warfield KL; Aman MJ
J Virol; 2016 Jan; 90(1):266-78. PubMed ID: 26468533
[TBL] [Abstract][Full Text] [Related]
4. Antibody-Mediated Protective Mechanisms Induced by a Trivalent Parainfluenza Virus-Vectored Ebolavirus Vaccine.
Kimble JB; Malherbe DC; Meyer M; Gunn BM; Karim MM; Ilinykh PA; Iampietro M; Mohamed KS; Negi S; Gilchuk P; Huang K; Wolf YI; Braun W; Crowe JE; Alter G; Bukreyev A
J Virol; 2019 Feb; 93(4):. PubMed ID: 30518655
[TBL] [Abstract][Full Text] [Related]
5. Cross-reactive neutralizing human survivor monoclonal antibody BDBV223 targets the ebolavirus stalk.
King LB; West BR; Moyer CL; Gilchuk P; Flyak A; Ilinykh PA; Bombardi R; Hui S; Huang K; Bukreyev A; Crowe JE; Saphire EO
Nat Commun; 2019 Apr; 10(1):1788. PubMed ID: 30996276
[TBL] [Abstract][Full Text] [Related]
6. Development and Characterization of Broadly Cross-reactive Monoclonal Antibodies Against All Known Ebolavirus Species.
Hernandez H; Marceau C; Halliday H; Callison J; Borisevich V; Escaffre O; Creech J; Feldmann H; Rockx B
J Infect Dis; 2015 Oct; 212 Suppl 2(Suppl 2):S410-3. PubMed ID: 25999057
[TBL] [Abstract][Full Text] [Related]
7. Structural Basis of Pan-Ebolavirus Neutralization by a Human Antibody against a Conserved, yet Cryptic Epitope.
West BR; Moyer CL; King LB; Fusco ML; Milligan JC; Hui S; Saphire EO
mBio; 2018 Sep; 9(5):. PubMed ID: 30206174
[TBL] [Abstract][Full Text] [Related]
8. Structural Biology Illuminates Molecular Determinants of Broad Ebolavirus Neutralization by Human Antibodies for Pan-Ebolavirus Therapeutic Development.
Murin CD; Gilchuk P; Crowe JE; Ward AB
Front Immunol; 2021; 12():808047. PubMed ID: 35082794
[TBL] [Abstract][Full Text] [Related]
9. Development of a Human Antibody Cocktail that Deploys Multiple Functions to Confer Pan-Ebolavirus Protection.
Wec AZ; Bornholdt ZA; He S; Herbert AS; Goodwin E; Wirchnianski AS; Gunn BM; Zhang Z; Zhu W; Liu G; Abelson DM; Moyer CL; Jangra RK; James RM; Bakken RR; Bohorova N; Bohorov O; Kim DH; Pauly MH; Velasco J; Bortz RH; Whaley KJ; Goldstein T; Anthony SJ; Alter G; Walker LM; Dye JM; Zeitlin L; Qiu X; Chandran K
Cell Host Microbe; 2019 Jan; 25(1):39-48.e5. PubMed ID: 30629917
[TBL] [Abstract][Full Text] [Related]
10. Early Human B Cell Response to Ebola Virus in Four U.S. Survivors of Infection.
Williamson LE; Flyak AI; Kose N; Bombardi R; Branchizio A; Reddy S; Davidson E; Doranz BJ; Fusco ML; Saphire EO; Halfmann PJ; Kawaoka Y; Piper AE; Glass PJ; Crowe JE
J Virol; 2019 Apr; 93(8):. PubMed ID: 30728263
[TBL] [Abstract][Full Text] [Related]
11. Proteo-Genomic Analysis Identifies Two Major Sites of Vulnerability on Ebolavirus Glycoprotein for Neutralizing Antibodies in Convalescent Human Plasma.
Gilchuk P; Guthals A; Bonissone SR; Shaw JB; Ilinykh PA; Huang K; Bombardi RG; Liang J; Grinyo A; Davidson E; Chen EC; Gunn BM; Alter G; Saphire EO; Doranz BJ; Bukreyev A; Zeitlin L; Castellana N; Crowe JE
Front Immunol; 2021; 12():706757. PubMed ID: 34335620
[TBL] [Abstract][Full Text] [Related]
12. Antibodies from a Human Survivor Define Sites of Vulnerability for Broad Protection against Ebolaviruses.
Wec AZ; Herbert AS; Murin CD; Nyakatura EK; Abelson DM; Fels JM; He S; James RM; de La Vega MA; Zhu W; Bakken RR; Goodwin E; Turner HL; Jangra RK; Zeitlin L; Qiu X; Lai JR; Walker LM; Ward AB; Dye JM; Chandran K; Bornholdt ZA
Cell; 2017 May; 169(5):878-890.e15. PubMed ID: 28525755
[TBL] [Abstract][Full Text] [Related]
13. Design and evaluation of bi- and trispecific antibodies targeting multiple filovirus glycoproteins.
Nyakatura EK; Zak SE; Wec AZ; Hofmann D; Shulenin S; Bakken RR; Aman MJ; Chandran K; Dye JM; Lai JR
J Biol Chem; 2018 Apr; 293(16):6201-6211. PubMed ID: 29500195
[TBL] [Abstract][Full Text] [Related]
14. Two Distinct Lysosomal Targeting Strategies Afford Trojan Horse Antibodies With Pan-Filovirus Activity.
Wirchnianski AS; Wec AZ; Nyakatura EK; Herbert AS; Slough MM; Kuehne AI; Mittler E; Jangra RK; Teruya J; Dye JM; Lai JR; Chandran K
Front Immunol; 2021; 12():729851. PubMed ID: 34721393
[TBL] [Abstract][Full Text] [Related]
15. Isolation of potent neutralizing antibodies from a survivor of the 2014 Ebola virus outbreak.
Bornholdt ZA; Turner HL; Murin CD; Li W; Sok D; Souders CA; Piper AE; Goff A; Shamblin JD; Wollen SE; Sprague TR; Fusco ML; Pommert KB; Cavacini LA; Smith HL; Klempner M; Reimann KA; Krauland E; Gerngross TU; Wittrup KD; Saphire EO; Burton DR; Glass PJ; Ward AB; Walker LM
Science; 2016 Mar; 351(6277):1078-83. PubMed ID: 26912366
[TBL] [Abstract][Full Text] [Related]
16. Multifunctional Pan-ebolavirus Antibody Recognizes a Site of Broad Vulnerability on the Ebolavirus Glycoprotein.
Gilchuk P; Kuzmina N; Ilinykh PA; Huang K; Gunn BM; Bryan A; Davidson E; Doranz BJ; Turner HL; Fusco ML; Bramble MS; Hoff NA; Binshtein E; Kose N; Flyak AI; Flinko R; Orlandi C; Carnahan R; Parrish EH; Sevy AM; Bombardi RG; Singh PK; Mukadi P; Muyembe-Tamfum JJ; Ohi MD; Saphire EO; Lewis GK; Alter G; Ward AB; Rimoin AW; Bukreyev A; Crowe JE
Immunity; 2018 Aug; 49(2):363-374.e10. PubMed ID: 30029854
[TBL] [Abstract][Full Text] [Related]
17. Novel Cross-Reactive Monoclonal Antibodies against Ebolavirus Glycoproteins Show Protection in a Murine Challenge Model.
Duehr J; Wohlbold TJ; Oestereich L; Chromikova V; Amanat F; Rajendran M; Gomez-Medina S; Mena I; tenOever BR; García-Sastre A; Basler CF; Munoz-Fontela C; Krammer F
J Virol; 2017 Aug; 91(16):. PubMed ID: 28592526
[TBL] [Abstract][Full Text] [Related]
18. Ebola virus can be effectively neutralized by antibody produced in natural human infection.
Maruyama T; Rodriguez LL; Jahrling PB; Sanchez A; Khan AS; Nichol ST; Peters CJ; Parren PW; Burton DR
J Virol; 1999 Jul; 73(7):6024-30. PubMed ID: 10364354
[TBL] [Abstract][Full Text] [Related]
19. Feverish Quest for Ebola Immunotherapy: Straight or Cocktail?
Saphire EO; Aman MJ
Trends Microbiol; 2016 Sep; 24(9):684-686. PubMed ID: 27338027
[TBL] [Abstract][Full Text] [Related]
20. Design and characterization of protective pan-ebolavirus and pan-filovirus bispecific antibodies.
Wirchnianski AS; Nyakatura EK; Herbert AS; Kuehne AI; Abbasi SA; Florez C; Storm N; McKay LGA; Dailey L; Kuang E; Abelson DM; Wec AZ; Chakraborti S; Holtsberg FW; Shulenin S; Bornholdt ZA; Aman MJ; Honko AN; Griffiths A; Dye JM; Chandran K; Lai JR
PLoS Pathog; 2024 Apr; 20(4):e1012134. PubMed ID: 38603762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
